To include your compound in the COVID-19 Resource Center, submit it here.

Investors sound alarm about pending drug pricing legislation

A quarter of a century ago, the threat of government price controls panicked investors, sparking a flight from the pharma sector that almost strangled the biotech industry in its infancy. Investors and biopharma executives, including many who survived the Clinton healthcare plan 26 years

Read the full 449 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers